Clinical Trial Update: A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial assessing MRG003 in combination with Pucotenlimab versus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• MRG003
• Pucotenlimab

Snippet

Sponsor: Shanghai Miracogen Inc. | Conditions: Recurrent or Metastatic Nasopharyngeal Carcinoma | Phase 3 | Status: RECRUITING